Cholinergic treatment: What are the early neuropathological targets?

European Journal of Neurology, Supplement

Volumn 12, Issue 3, 2005, Pages 3-9

  Riepe, Matthias W ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Dementia; Donepezil; Hippocampus; Neuropathology; Neuroprotection

Indexed keywords

3 NITROPROPIONIC ACID; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; DIZOCILPINE; DONEPEZIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GALANTAMINE; GLUCOSE; LACTATE DEHYDROGENASE; N ACETYLASPARTIC ACID; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; BRAIN CELL; BRAIN HYPOXIA; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; HIPPOCAMPUS; HUMAN; IC 50; MAJOR DEPRESSION; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SPATIAL ORIENTATION; SYSTEMATIC REVIEW; TRANSGENIC MOUSE;

EID: 27144479875     PISSN: 14710552     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2005.01321.x     Document Type: Conference Paper

References (25)

1. Akasofu S, Kosasa T, Kimura M, Kubota A (2003). Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygen-glucose deprivation. Eur J Pharmacol 472:57-63.
2. Arnal F, Cote LJ, Ginsburg S, Lawrence GD, Naini A, Sano M (1990). Studies on new, centrally active and reversible acetylcholinesterase inhibitors. Neurochem Res 15:587-591.
3. von Arnim CA, Hellweg R, Buchner M, Huber R, Riepe MW (2005). Regional selectivity of amyloid mRNA expression and neurotrophins on repetitive inhibition of oxidative phosphorylation. J Neural Transm 112:491-498.
4. Braak H, Braak E (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82:239-259.
5. Buchner M, Huber R, Sturchler-Pierrat C, Staufenbiel M, Riepe MW (2002). Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice. Neuroscience 114:285-289.
6. Choi DW, Maulucci-Gedde M, Kriegstein AR (1987). Glutamate neurotoxicity in cortical cell culture. J Neurosci 7:357-368.
7. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E (2001). A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57(11):2153]. Neurology 57:613-620.
8. Gron G, Riepe MW (2004). Neural basis for the cognitive continuum in episodic memory from health to Alzheimer disease. Am J Geriatr Psychiatry 12:648-652.
9. Gron G, Wunderlich AP, Spitzer M, Tomczak R, Riepe MW (2000). Brain activation during human navigation: gender-different neural networks as substrate of performance. Nat Neurosci 3:404-408.
10. Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW (2002). Subjective memory complaints: objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 51:491-498.
11. Gron G, Brandenburg I, Wunderlich AP, Riepe MW (2005). Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging, in press.
12. Hellweg R, von Arnim CA, Buchner M, Huber R, Riepe MW (2003). Neuroprotection and neuronal dysfunction upon repetitive inhibition of oxidative phosphorylation. Exp Neurol 183:346-354.
13. Hodges JR (2000). Memory in the dementias. In: Tulving E, Craik FIM, eds. The Oxford Handbook of Memory. Oxford University Press, Oxford, UK, pp. 441-459.
14. Kaasinen V, Nagren K, Jarvenpaa T et al. (2002). Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease. J Clin Psychopharmacol 22:615-620.
15. Kitagawa K, Matsumoto M, Tagaya M et al. (1990). 'Ischemic tolerance' phenomenon found in the brain. Brain Res 528:21-24.
16. Krishnan KR, Charles HC, Doraiswamy PM et al. (2003). Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 160:2003-2011.
17. Nakano S, Asada T, Matsuda H, Uno M, Takasaki M (2001). Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease. J Nucl Med 42:1441-1445.
18. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000). Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 22:609-613.
19. Rakonczay Z (2003). Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung 54: 183-189.
20. Riepe MW, Niemi WN, Megow D, Ludolph AC, Carpenter DO (1996). Mitochondrial oxidation in rat hippocampus can be preconditioned by selective chemical inhibition of succinic dehydrogenase. Exp Neurol 138:15-21.
21. Takada Y, Yonezawa A, Kume T et al. (2003). Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306:772-777.
22. Tang XC (1996). Huperzine A (Shuangyiping): a promising drug for Alzheimer's disease. Acta Pharmacol Sin 17: 481-484.
23. Wiegand F, Liao W, Busch C et al. (1999). Respiratory chain inhibition induces tolerance to focal cerebral ischemia. J Cereb Blood Flow Metab 19:1229-1237.
24. Zhou J, Fu Y, Tang XC (2001a). Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation. Neurosci Lett 306:53-56.
25. Zhou J, Zhang HY, Tang XC (2001b). Huperzine A attenuates cognitive deficits and hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 313:137-140.